NCT02737787View on ClinicalTrials.gov

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 6, 2023

Study Completion Date

April 6, 2023

Conditions
Ovarian CancerFallopian TubePrimary Peritoneal CancerRecurrent Ovarian Cancer
Interventions
BIOLOGICAL

WT1 Vaccine

DRUG

Nivolumab

Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.

BIOLOGICAL

NY-ESO-1 Vaccine

Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre

11725

Memorial Sloan Kettering Commack (All Protocol Activities), Commack

Unknown

Memorial Sloan Kettering Cancer Center (All Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02737787 - A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter